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Background: Up to 30% of patients with schizophrenia are resistant to antipsychotic drug treatment, with 60%
of such cases also failing to respond to clozapine. Deep brain stimulation (DBS) has been used in treatment
resistant patients with other psychiatric disorders, but there is a lack of trials in schizophrenia, partly due to
uncertainties over where to site the electrodes. This trial aimed to examine the effectiveness of nucleus
accumbens (NAcc) and subgenual anterior cingulate cortex (subgenual ACC) targeted DBS; the primary out-
come measure was PANSS total score, as assessed fortnightly.
Methods: Eight patients with schizophrenia, who met criteria for treatment resistance and were also resistant to/
intolerant of clozapine, were randomly assigned using central allocation to receive DBS in the NAcc or subgenual
ACC. An open stabilization phase lasting at least six months was followed by a randomized double-blind cross-
over phase lasting 24 weeks in those who met symptomatic improvement criteria. The primary end-point was a
25% improvement in PANSS total score. (ClinicalTrials.gov Identifier: NCT02377505; trial completed).
Findings: One implanted patient did not receive DBS due to complications of surgery. Of the remaining 7
patients, 2/3 with NAcc and 2/4 with subgenual ACC electrode placements met the symptomatic improve-
ment criteria (58% and 86%, and 37% and 68% improvement in PANSS total score, respectively). Three of these
patients entered the crossover phase and all showed worsening when the stimulation was discontinued. The
fourth patient worsened after the current was switched off accidentally without her or the investigators’
knowledge. Physical adverse events were uncommon, but two patients developed persistent psychiatric
adverse effects (negative symptoms/apathy and mood instability, respectively).
Interpretation: These preliminary findings point to the possibility of DBS having therapeutic effects in patients with
schizophrenia who do not respond to any other treatment. Larger trials with careful attention to blinding will be
necessary to establish the extent of the benefits andwhether these can be achievedwithout psychiatric side-effects.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)talaries Research Foundation,
rcelona, Spain.
enna).
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Schizophrenia is a severe and disabling mental disorder character-
ized by positive, negative and cognitive symptoms, affecting around
1% of the population worldwide [1]. It is estimated that around
Research in Context
Evidence before this study
Poor response to antipsychotic drug treatment is a well-recognized
problem in schizophrenia. Deep brain stimulation (DBS) has been
used in treatment resistant major depression and obsessive-com-
pulsive disorder, but trials are so far lacking in schizophrenia. Liter-
ature review to confirm the absence of existing trials included (a)
searching PubMed using the terms deep brain stimulation and
schizophrenia and checking the references of all relevant publica-
tions; (b) checking ClinicalTrials.gov; and (c) personal communica-
tion with the investigators of a currently recruiting American trial.
Added value of this study
This initial trial suggests that DBS might be beneficial in some
patients with treatment resistant schizophrenia. Of particular
note was the near-complete disappearance of positive symp-
toms (delusions and hallucinations) in two patients with
nucleus accumbens electrode placements.
Implications of all the available evidence
The apparent positive effects of DBS in schizophrenia in this
trial need to be treated with caution given the small numbers
and mainly open label evaluation. It will also be important to
determine whether and to what extent clinical improvement
can be obtained without psychiatric adverse effects.
2 I. Corripio et al. / EBioMedicine 51 (2020) 1025682030% of patients are resistant to conventional antipsychotic drug
treatment [2], and less than half of such patients (40.1%, 95% confi-
dence interval 36.8%43.4%) respond to the most effective of the sec-
ond-generation or atypical antipsychotics, clozapine [3]. Other
psychopharmacological strategies, in particular the use of a range of
drugs with glutamatergic actions, have so far failed to fulfil their
promise, either for negative symptoms [4] or for all symptoms [5].
Deep brain stimulation (DBS) is a well-established treatment for
Parkinson’s disease and other movement disorders, whose use has
been extended in recent years to treatment resistant psychiatric ill-
ness [6]. The technique involves high frequency stimulation of deep
brain areas through electrodes implanted under stereotactic surgery.
It is believed to work primarily by producing functional inhibition in
the region around the electrode, but excitatory effects on local axons
and more distant excitatory effects may also play a part [7]. It has
additionally been argued that the intervention may act in the longer
term to correct pathological brain activity in brain networks with
connections to the implantation site [8]. Importantly, unlike other
forms of psychosurgery, DBS is reversible, i.e., the stimulation can be
turned off (and if necessary the electrodes explanted) without any
permanent loss of function.
To date, DBS has been employed principally in treatment resistant
patients with two psychiatric disorders, obsessive-compulsive disor-
der and major depression, with broadly encouraging results in both
cases [9,10]. The electrode placements most frequently employed
have been in or around the nucleus accumbens (NAcc) in the former
disorder [9], and in this site and the subgenual anterior cingulate cor-
tex (subgenual ACC) in the latter [10]. The potential use of DBS in
treatment resistant schizophrenia is currently a topic of considerable
discussion [11,12], with much of the debate focusing on where to site
the electrodes. Practical experience, in contrast, is virtually non-exis-
tent. Plewnia et al. [13] reported beneficial effects of DBS on obses-
sions and compulsions using an NAcc electrode placement in a
patient with residual schizophrenia, but this patient had no psychotic
symptoms. A trial in Toronto (Clinicaltrials.gov identifierNCT01725334) aimed to use electrode placements in the NAcc or the
ventral tegmental area, with the aim of improving negative symp-
toms; however, this trial was abandoned due to lack of recruitment.
A currently recruiting trial in Baltimore (Clinicaltrials.gov indentifier
NCT02361554), targets the substantia nigra pars reticulata; its ratio-
nale is that local inhibitory effects will result in disinhibition of the
mediodorsal thalamic nucleus and lead to improvement in positive
and cognitive symptoms.
We report the outcome of the first completed trial of DBS in treat-
ment resistant schizophrenia. Because of the uncertainties concern-
ing electrode placement we decided to test the effectiveness of two
targets. One was in the ventral striatum, specifically the NAcc, and
the other was the subgenual ACC. Choice of these two sites was
driven partly by the fact that both have been employed in obsessive-
compulsive disorder and/or major depression, and partly because
both sites can be considered to be in some sense characterized by
neuronal overactivity in schizophrenia, and so potentially susceptible
to the functional inhibitory effects of DBS. In the case of the NAcc
there is longstanding circumstantial evidence for a functional dopa-
mine excess in the disorder [14], with current findings pointing to
increased dopamine synthesis capacity in the striatum [15]. At a the-
oretical level positive symptoms (in particular delusions and halluci-
nations) have also been linked to ventral striatal overactivity via
Kapur’s [16] influential ‘aberrant salience’ proposal, of increased and
inappropriate dopamine activity giving rise to abnormal reward pre-
diction error signals. Also relevant to the decision to employ a ventral
striatal electrode placement is the fact that this part of the basal gan-
glia receives major afferent input from the hippocampus, which has
been considered to play a role in the pathophysiology of schizophre-
nia and has been proposed as a target for DBS [11].
The choice of a subgenual ACC placement was based on the find-
ing of failure of de-activation in the medial frontal cortex, described
by ourselves [17] and others [18]. This failure is presumed to reflect
dysfunction in the so-called default mode network, a set of brain
regions that are normally active at rest but which de-activate during
performance of a wide range of attention-demanding tasks; the
medial frontal cortex  including the pregenual and subgenual por-
tions of the anterior cingulate cortex, but also more rostral regions 
forms one of two prominent midline ‘nodes’ or ‘hubs’ of this network
[19]. On these grounds, the medial frontal cortex represents a more
logical cortical target for the local inhibitory effects of DBS than the
dorsolateral prefrontal cortex, which is also implicated in schizophre-
nia but where the abnormality takes the form of hypofunction [20].
In this paper we report clinical and functional outcomes from the
trial. Neuropsychological and functional imaging findings will be
reported in future communications.
2. Methods
2.1. Design
The trial had a combined open (6+ month) and double-blind
crossover (24 weeks) design. The 24-week crossover phase length
was based on previous experience by one of the two groups of inves-
tigators with DBS for depression [21]. The aim was to recruit 8
patients who would be randomly assigned 1:1 to electrode place-
ments in either the NAcc or the subgenual ACC. This study is regis-
tered with ClinicalTrials.gov (identifier NCT02377505).
2.2. Participants
Patients were recruited from the outpatient, inpatient and residen-
tial facilities of two mental healthcare organizations in Barcelona: FID-
MAG Germanes Hospitalaries and the Hospital de la Santa Creu i Sant
Pau, plus referrals by other interested clinicians. Inclusion criteria were:
age 1855 years, having a diagnosis of schizophrenia according to
I. Corripio et al. / EBioMedicine 51 (2020) 102568 3DSM-IV criteria, having a five-year minimum duration of illness and
showing evidence of treatment resistance. For treatment resistance the
following were required: (a) presence of continuing positive symptoms
without remission for two years; (b) poor response to treatment with at
least two different antipsychotics, including at least one atypical anti-
psychotic (not including clozapine) given in adequate doses for a period
of at least 6 weeks; and (c) having been treated with clozapine with
either no improvement at adequate dosage or poor tolerance. It was
anticipated that most patients would also show negative symptoms, but
presence of these was not an inclusion criteria. While not forming part
of current definitions of treatment resistance, we added a requirement
that the patients had been treated with ECT at some point without sus-
tained improvement, unless this treatment was contra-indicated or not
tolerated or had been refused. This was in the interests of focusing on
patients in whom all other potentially effective treatment options had
been tried [22].
At the time of study entry the patients were required to have a
score of 4 (moderate) or greater on at least two of the Positive and
Negative Symptoms Scale (PANSS) items, delusions, hallucinatory
behaviour, suspiciousness, unusual thought content, or alternatively
a score of 6 (severe) or greater on one symptom. They also had to
score 6 or greater (severely ill) on the Clinical Global Impression
(CGI) scale and to have been on stable doses of treatment for at least
two months. Women of childbearing age had to have a negative preg-
nancy test within 72 h pre-study and had to be using contraception.
Exclusion criteria included: (a) contraindications to neurosurgery or
DBS (e.g. pacemaker); (b) diagnosis of epilepsy or clozapine-induced
seizures currently requiring treatment with anticonvulsants; (c) pres-
ence of suicidal or self-harming behaviour or ideation in the last two
years; (d) significant cognitive impairment, as defined by WAIS III IQ
<70, or performance in the severely impaired range on memory or
executive function tests on more detailed neuropsychological testing;
(e) presence of significant cardiovascular and/or cerebrovascular disease
(defined as history of cerebrovascular events, clinical symptoms of car-
diac or vascular disease, ischaemic changes on ECG, uncontrolled hyper-
tension); (f) if female, breastfeeding; (g) history of drug or alcohol
abuse/dependency in the previous two years.
Only patients who were able to fully understand the potential
benefits and risks of treatment were considered for the trial. The con-
sent process was rigorous, and included discussions with both the
patient and his/her family if appropriate. Patients were also required
to have a caregiver or identified responsible person (i.e., family mem-
ber, social worker, case-worker, or nurse) who spent at least four
hours/week with the patient and was able to provide advice and sup-
port concerning the study procedures. A committee including the
patient’s psychiatrist, an independent senior psychiatrist and a neu-
rosurgeon further considered the feasibility of enrolling each patient
into the study.
The patients were randomly assigned 1:1 to one of the two elec-
trode placements using PROC PLAN of SAS (version 9). Randomization
was carried out by central allocation using computer generated ran-
dom numbers: an independent statistician from another department
generated the list, assigned the target sequence and communicated it
to one of the investigators in a sealed envelope. This investigator
communicated the target to the neurosurgeons. A block randomiza-
tion method was used. A similar procedure was followed for the ran-
domization in the crossover phase (which also took into account the
first randomization to ensure balanced allocation within the targets).
After undergoing surgery to implant the electrodes, stimulation was
started within 4872 h and lasted until the patient was clinically sta-
ble, with a minimum period of 6 months. If the patient achieved
symptomatic response (defined as an improvement  25% in PANSS
total score, calculated using the formula: [PANSS baseline score 
PANSS post-scores] £ 100/ [PANSS baseline score-30] [23], which
was maintained in at least 50% of the subsequent PANSS ratings, he
or she then entered the 24-week double-blind crossover phase, andwas randomized to 12 weeks with the stimulation ‘on’ followed by
12 weeks ‘off’ or vice-versa. In case of worsening, the patient could
be withdrawn from the study if necessary and the stimulation turned
on again (if it was currently switched off). Pharmacological treatment
could not be modified throughout the study period, except for pre-
scription of benzodiazepines or hypnotics if required.
All patients gave written informed consent. The study was in line
with the Declaration of Helsinki, and was approved by the hospital
ethical committee and the Spanish regulatory drug agency (Agencia
Espa~nola de Medicamentos y Productos Sanitarios).2.3. Assessments
In addition to PANSS total score, which was the primary outcome
measure, and its positive and negative subscales, assessments
included the Psychotic Symptom Rating Scales (PSYRATS) [24], the
Scale for the Assessment of Negative Symptoms (SANS) [25], the Cal-
gary Depression Scale for Schizophrenia (CDSS) [26] and the Global
Assessment of Functioning scale (GAF) [27]. Two social functioning
scales were also used, the Personal and Social Performance (PSP)
Scale [28] and the Social Functioning Scale [29].
Symptomatic changes were evaluated every two weeks with the
PANSS until the end of the trial. The remaining clinical scales were
administered at the main study points (i.e., baseline, immediately
before the crossover phase and at termination). Adverse events were
assessed in detail monthly by the member of the trial team perform-
ing the psychiatric and social evaluations. Following termination
from the trial patients continued to be followed up by members of
the trial team or their treating clinicians.
In the stabilization phase the assessors were blind to which elec-
trode placement each patient had and to any changes in stimulation
parameters that were made. Both the patients and the clinicians
were unaware of the patients’ stimulation status during the crossover
phase. Measures to assess the success of blinding were not employed.2.4. Surgical procedure
Electrode implantation was in the white matter adjacent to the
Cg25 region (subgenual ACC) and in the NAcc. The DBS pulse-gener-
ating device was implanted abdominally. Prior to surgery, a Leksell G
stereotactic frame (Elekta Instruments, Atlanta, GA, USA) was fitted
to the patient’s head. Using the StealthStation 7 (Medtronic Inc., Min-
neapolis, MN, USA) the CT scan with the stereotactic frame was fused
to the MRI image to calculate the surgical targets. The target subge-
nual ACC white matter was delimited as follows: in a midline T2 sag-
ittal image the cingulate gyrus inferior to the genu of the corpus
callosum was identified; next, a line was traced from this point of the
corpus callosum to the anterior commissure and the mid-point was
identified; an image was then taken of the T2 coronal section corre-
sponding to the plane of the mid-point and the definitive coordinates
were calculated for the transition area between the white and grey
matter for BA 25. The NAcc target was determined measuring the dis-
tances from the anterior commissure (AC) and the posterior commis-
sure (PC) with the following coordinates: x = 68 mm lateral to
midpoint, y = 13 mm anterior to the AC, Z = 4 mm inferior to the AC
line (see Fig. 1 for location of the NAc and subgenual ACC electrode
implantations in subjects N5 and N7, respectively). In the operating
room, with the patient under general anaesthesia, a burr hole was
drilled in front of the coronal suture and laterally at a variable dis-
tance from the midline seeking to avoid the ventricles. DBS electro-
des (Medtronic model 3387, Medtronic Inc., Minneapolis, MN, USA)
were implanted bilaterally. Each of the four electrode contacts was
tested intraoperatively at maximal voltage (9.0 V). During the same
surgical procedure, a programmable internal pulse generator (Activa
PC, Medtronic Inc., Minneapolis, MN, USA) was implanted
Fig 1. Location of the deep brain stimulation leads in the (A) nucleus accumbens (NAcc) and in the (B) subgenual anterior cingulate cortex (subgenual ACC) in right and left hemi-
spheres. The upper row of images corresponds to coronal and sagittal slices; the lower images correspond to axial section in 2D and 3D views. The 3D plane shows a volumetric
reconstruction of both targets (bilateral NAcc in metallic blue; left subgenual ACC in purple, right subgenual ACC in blue. Images were generated using the SureTune software (Med-
tronic Eindhoven Design centre, MEDC).
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out under general anaesthesia.
Stimulation was started 4872 h after surgery using unilateral left
stimulation, (contact anode, case cathode), with the initial following
parameters: 2.5 V, 60 microseconds (ms) pulse width and 130 Hertz
(Hz) of frequency; these were chosen based on prior experience by
our group (Sant Pau) with DBS in patients with major depression.
Two contacts with good levels of impedance were selected taking
into account the position of the electrode within the selected area
(e.g., patient N1 showed had a contact outside the NAcc and so this was
not used). After a week bilateral stimulation was begun, again based on
previous clinical experience with DBS in psychiatric populations.
During the stabilization phase stimulation parameters were modi-
fied individually for each patient by an independent clinician
depending on clinical state, and guided specifically by the presence
and degree of positive symptoms. Patients were not informed about
any changes. The sequence of changes to maximize the therapeutic
effect was (1) increasing voltage up to 7.5 V, (2) increasing pulse
width or frequency up to 210 ms/Hz, and (3) changing active contacts
or mode.
2.5. Data analysis
Formal analysis of changes in PANSS and other ratings was con-
sidered to be of limited value due to the small sample size, and is also
complicated by the fact that the endpoint criteria (i.e., progression to
crossover phase or termination due to lack of effectiveness)
depended on response to DBS. For completeness, however, statistical
models were fitted to the PANSS data (PANSS total, PANSS positive,
PANSS negative) for the sample as a whole (i.e., not separating by
electrode placement), considering only the stabilization phase. Linear
mixed models with repeated measures evaluated the effect of DBS by
considering the PANSS scores in the visit previous to the surgical
implant and all the subsequent assessments up till the end of the sta-
bilization phase. This model also tested the effect of time (evolution
of PANSS scores across time, discounting the DBS off-on effect)
including also individual slopes and intercepts (i.e., the random
effects part of the model). Paired t-tests were additionally carried
out, considering individual PANSS scores at the baseline visit and at
the last recorded visit in the stabilization phase. Statistical analyses
were conducted with version 3.6.0 of the R software.
2.6. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation or writing of the report. The
corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
3. Results
3.1. Patient characteristics
Slightly less than thirty patients were considered for the trial
(Sant Pau N = 14; FIDMAG N = 1315, exact numbers not recorded).
The most common reason for exclusion was a lack of perceived need
for treatment by the patient. Other reasons in individual cases
included failure to meet diagnostic criteria, ongoing substance abuse,
presence of comorbid psychiatric disorder (obsessive-compulsive
disorder and autistic spectrum disorder) and failure to meet severity
criteria.
Eight patients were enrolled in the study. The first patient was
recruited on 28/11/2014 and the last on 20/04/2017. One patient
(N3) did not proceed to stimulation; he suffered a right internal cap-
sule haemorrhage immediately after surgery and subsequently
developed infection in the device which threatened to spread to theelectrodes. As a result the generator and electrodes were removed
three months after surgery.
All but one of the seven remaining patients showed ultra-treat-
ment resistant illness, according to Howes et al. [30]. In the remaining
patient (N6) clozapine was not tolerated at doses higher than
100 mg/day (the dose she was taking at study entry). These seven
patients’ baseline characteristics and electrode placement after first
randomization are shown in Table 1. Three patients were implanted
in the NAcc (N1, N5, N6) and 4 patients in the subgenual ACC (N2, N4,
N7, N8). All patients were receiving treatment with clozapine aug-
mented with different antipsychotics. Highest stimulation parame-
ters achieved during the study period in each patient are shown in
supplementary Table S1.3.2. Stabilization phase
The open stabilization phase lasted between 8 and 20 (average 13)
months. Average scores over first eight months of treatment (the
period during which all patients remained in the stabilization phase),
separated according to electrode placement, are shown in Fig. 2. Indi-
vidual scores for the patients over the entire stabilization phase are
shown in Supplementary Figs. S1 and S2. It is noteworthy that two of
the three patients with NAcc placements showed a nearly full remis-
sion (N1) and full remission apart from intermittent recurrences (N6)
of positive symptoms (which took the form exclusively of delusions
and hallucinations in both cases). One of these patients (N1) has been
reported previously [31].
Given the limitations of applying statistical analysis to the data,
detailed results are reported in the Supplementary material. Briefly,
however, testing across the whole sample (N = 7) revealed a signifi-
cant effect of DBS on PANSS total, positive symptoms and negative
symptoms scores (all p<0.001), when the baseline (i.e., DBS off) was
compared to all remaining time points in the stabilization phase (i.e.,
DBS on) using a repeated measures linear mixed model. This result
was replicated for PANSS total score and positive symptoms score,
but not negative symptoms score, when a simpler paired t-test was
performed, considering the baseline (DBS off) and last observation
(DBS on) (PANSS total p = 0.007; PANSS positive p = 0.002; PANSS
negative p = 0.18).3.3. Double-blind crossover phase
Four patients (N1, N2, N4 and N6) met the symptomatic response
criteria, 2 with NAcc (N1 and N6) and 2 (N2 and N4) with subgenual
ACC placements (for percentages of improvement see Supplementary
Table S2). Three of these patients entered the crossover phase. Patient
N1 (NAcc placement) entered in an ‘on’ phase. Six weeks after the
stimulation was switched to ‘off’ a worsening in psychotic symptoms
became evident, which took the form mainly of a worsening of nega-
tive symptoms [PANSS scores immediately before entering crossover
and in the first switch-off visit where a worsening of symptoms was
evident: total: 64 vs. 73, positive symptoms: 14 vs. 14, negative
symptoms: 16 vs. 21]. This patient remained in the trial until the end
of the crossover phase. Patient N2 (subgenual ACC placement) began
in an ‘off’ phase. This was followed by a worsening of psychotic
symptoms within a few days [PANSS scores: total: 79 vs. 98, positive
symptoms: 17 vs. 23, negative symptoms: 18 vs. 24]. The patient was
admitted with suicidal ideation, the stimulation was switched back
on, and he was withdrawn from the study. Patient N4 (subgenual
ACC placement) also began in an ‘off’ phase and also showed a wors-
ening of psychotic symptoms, in this case two weeks later [PANSS
scores: total: 47 vs. 93, positive symptoms: 16 vs. 25, negative symp-
toms: 13 vs. 29. The stimulation was switched back on, and the
patient was withdrawn from the study. Details of the three patients’
courses during the crossover phase are summarized in Fig. 3.
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6 I. Corripio et al. / EBioMedicine 51 (2020) 102568The fourth patient who met the symptomatic response criteria (N6,
NAcc placement) achieved excellent remission of psychotic symptoms,
although these intermittently returned, requiring frequent alterations of
stimulus parameters. After 10 months in total, at a time when she had
been symptom free for several weeks, the stimulation was turned off
unknown to the patient and the investigators. (What happened is
unclear but possibilities include either that the off button had been acci-
dentally touched when her stimulus parameters were checked during a
clinic visit, or that the stimulator function was interrupted when she
passed through a security scanner at a tourist attraction the same day.)
Her symptoms (delusions and auditory hallucinations) returned within
24 h and persisted until the switching off event was discovered a few
days later. The patient reported subjective improvement 20 min after
the current was turned back on. The next day she was symptom free.
The patient was given the option of formally entering the crossover
phase, but declined.
Two spontaneous disconnections also occurred in N5 (NAcc place-
ment) at the beginning of treatment. These lasted less than a week
on both occasions and were not obviously associated with clinical
changes.
3.4. Secondary outcomes
Average PSYRATS and SANS scores from baseline to randomiza-
tion or termination for all 7 patients are shown in Table 2. Mirroring
the pattern with the PANSS, reductions were evident on both scales.
Depression scores also decreased. Improvements were also seen on
the GAF and CGI. There was evidence of improvement on one of the
two social functioning scales used, the PSP (see Table 2), but not on
the other, the SFS (see Supplementary Table S3).
3.5. Adverse events
DBS was generally well-tolerated in the 7 patients who proceeded
to electrode activation. However, one patient with an NAcc place-
ment (N1) developed akathisia after the stimulation was changed
from unilateral to bilateral; this eventually responded when the stim-
ulation was changed back to unilateral, maintaining the reduced
parameters. As noted, during the crossover phase this patient devel-
oped worsening of negative symptoms from a previously mild level.
This worsening has persisted, despite DBS being resumed and subse-
quent alterations in the stimulation parameters.
Patient N5 described an electrical sensation in his trunk and his head
that occurred occasionally and depended on certain body movements.
Examination, including neuroimaging, did not reveal evidence of device
malfunction (e.g., damaged electrodes or wire connections to the inter-
nal pulse generator). Changing of the stimulation from unipolar to bipo-
lar mode was followed by a resolution of the symptom.
After trial end, after 11 months of stimulation in total, patient N6
developed behavioural changes compatible with hypomania. Imme-
diately prior to this she had taken a unilateral decision to stop taking
antipsychotic medication. Stimulation parameters were initially low-
ered with a certain amount of improvement. However, six weeks
later she was admitted in a mixed affective state, which responded to
treatment with antipsychotics. Since then the patient’s clinical state
has been characterized by mood instability with fluctuations on a
daily basis, impulsive behaviour and at times suicidal ideation. These
symptoms initially proved difficult to control with mood stabilizers
and changes to her DBS parameters, although her mood fluctuations
improved after re-instatement of antipsychotic medication (aripipra-
zole). Currently she is free of prolonged periods of mood disturbance,
although she continues to experience spells of depression lasting
hours or days. Her psychotic symptoms (referential delusions accom-
panied by auditory hallucinations) have remained in remission most
of the time, though they are prone to re-appear for periods of
1236 h, often when she is under stress.
Fig 2. Symptomatic changes in the 7 DBS treated patients over the first 8 months of the stabilization phase.
I. Corripio et al. / EBioMedicine 51 (2020) 102568 73.6. Post-operative course in the patient who did not receive DBS
After suffering a right-sided peri‑operative haemorrhage, patient
N3 initially showed confusion which lasted four days. After this set-
tled he was noted to show improvement in his previously severe
active psychotic symptoms. This improvement remained evident for
over seven months, but hallucinations and referential delusions ulti-
mately re-appeared, although less severely than before the opera-
tion.
Six months after being withdrawn from the trial, the patient
showed no neurological signs, though he had experienced seizures
which were controlled with anticonvulsant medication. He shows a
lesion in the anterior right internal capsule.
4. Discussion
To our knowledge, this is the first study reporting the effective-
ness and safety of DBS in patients with treatment resistant schizo-
phrenia, all but one of whom were also resistant to clozapine.
Although the sample size was small and the variability in treatment
response makes it difficult to generalize, there were indications of
improvement, with the NAcc appearing to be the more promising of
the two placements employed. Caution is necessary before accepting
improvement observed under open conditions at face value. How-
ever, three of the four patients who showed significant improvement
worsened when the current was switched off under double-blind
conditions; the fourth patient also worsened abruptly when the
device was accidentally switched off without her or her clinicians’
knowledge.
Two out of the three patients with NAcc targeted DBS met the
symptomatic improvement criterion. In these patients the improve-
ment in their main symptoms, delusions and hallucinations, was
marked, taking the form of a near complete disappearance (patient
N1) and complete absence of these symptoms most of the time(patient N6). As noted in the Introduction, the NAcc and the ventral
striatum of which it forms part is a plausible target for the local func-
tional inhibitory effects of DBS, as it is strongly suspected of being a
site of functional overactivity in schizophrenia, specifically increased
dopaminergic activity. Nevertheless, it should be noted that func-
tional imaging studies in schizophrenia have uniformly found that
ventral striatal activation in response to reward predictive stimuli is
reduced rather than increased as the salience theory predicts [32].
On this basis it is unclear why a functional inhibition produced by
DBS would have an ameliorative effect on positive symptoms. Possi-
ble explanations for this inconsistency might be in terms of the local
or more distant excitatory effects of DBS [7], or possibly in terms of
modulatory effects on the mesolimbic and mesocortical components
of the mesotelencephalic dopamine projection [11].
In the patients with electrode placements in the subgenual ACC,
improvement appeared less marked and, in the two who went on to
meet improvement criteria, was more gradual (see individual graphs
in Supplementary Fig. S2). Why this should be so is unclear. However,
as noted by Veerakumar and Berton [8], while the motor effects of
DBS in neurological disorders are immediate, the response in psychi-
atric disorders such as major depression is typically of the order of
weeks to months, suggesting that longer-term effects on brain net-
works of which the implantation site forms part may be relevant.
As noted in the Introduction, our choice of sites for electrode
placements was guided by a combination of evidence from its use in
other psychiatric disorders and pathophysiological findings from
patients with the disorder itself. Relevant findings from animal stud-
ies have also recently become available and may potentially provide
further insights into the mechanism of DBS in schizophrenia. Thus,
Bikovsky et al. [33] examined the effects of DBS in an animal model
of schizophrenia in which pregnant females were administered a
viral mimic (polyinosinic-polycytidilic acid, poly I:C). The progeny of
mothers administered these or other similar agents have been found
to show a variety of behavioural and neuropathological changes
Fig 3. Changes in PANSS total, positive and negative scores in the three patients who entered the crossover phase.
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or early adulthood; they also show decreased prepulse inhibition and
disrupted latent inhibition. DBS administered in both the NAcc and
the medial prefrontal cortex to such rats in adulthood was found to
reduce abnormalities in both prepulse inhibition and latent inhibi-
tion.
DBS was physically well-tolerated in the seven patients who pro-
ceeded to electrode activation. The only major physical adverse event
was akathisia in one patient with a NAcc placement which appeared
after stimulation was changed from unilateral to bilateral; this
improved when the stimulation was changed back to unilateral [31].
On the other hand, lasting psychiatric adverse effects were promi-
nent in the two patients with NAcc placements whose positive symp-
toms improved. One (N1) developed an amotivational state duringthe crossover phase that has since proved resistant to all interven-
tions. The features of this state are consistent with negative schizo-
phrenic symptoms, but apathy is also a recognized side-effect of DBS
in Parkinson’s disease [34]. The other patient (N6) developed mood
instability that has so far lasted over a year, though with a gradually
improving course. Depression and mood elevation, which can some-
times be prolonged, are also recognized complications of DBS for Par-
kinson’s disease with a variety of different electrode placements [34].
It may also be relevant that while this patient was given a diag-
nosis of schizophrenia before trial entry, lifetime structured psy-
chiatric interview at that time revealed a previous one-month
episode when, after her antipsychotic medication was changed,
she developed erotomanic ideation and showed flight of ideas;
psychotic symptoms remained present during this period. It
Table 2
Changes in other scales from baseline to randomization or termination.
Mean score at baseline
(§SD)
Mean score at
randomization/
termination (§SD)
PSYRATS (sum of delu-
sion and hallucination
subscales
44.71§12.65 32.57§21.79
SANS (total score) 55.57§12.97 46.29§23.43
CDSS 7.29§6.21 3.71§4.79
GAF 31.14§4.49 47.14§17.07
CGI 6 § 0.0 4.14§1.68
Personal and Social Per-
formance Scale*
30.83§8.49 42.67§25.91
* Based on 6 patients, data missing at randomization/termination for 1 patient.
For scores on the Social Functioning Scale see Supplementary Table S3.
PSYRATS  Psychotic Symptom Rating Scales; SANS  Scale for the Assessment of
Negative Symptoms; CDSS  Calgary Depression Scale for Schizophrenia; GAF 
Global Assessment of Functioning scale; CGI  Clinical Global Impression of
Severity.
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schizoaffective disorder.
In conclusion, this small initial trial of DBS in schizophrenia pro-
vides grounds for considering that it may be useful in some treatment
resistant and ultra-treatment resistant patients. There were sugges-
tions that the NAcc placement had greater beneficial effects than that
in the subgenual ACC, though this finding could easily be overturned
in a larger trial. NAcc-targeted DBS also seemed to be particularly
effective in patients with a clinical picture characterized mainly by
delusions and hallucinations. One of the eight patients implanted suf-
fered a serious complication (internal capsule haemorrhage), though
fortunately this was without serious long-term sequelae. This fre-
quency has to be contrasted with experience from DBS in neurologi-
cal disorders, where the risk of neurosurgical complications,
including infection and haemorrhage, have been estimated to be
13% [35]. Additionally, in the two patients in whom marked
improvement was seen, this came at a cost of significant psychiatric
complications. The main limitation of this trial is its small sample
size. Additionally, the 24 week duration of the crossover phase may
have been insufficient to fully dissipate carryover effects. The fact
that, out of the three patients who entered the double-blind cross-
over phase, the two randomized to ‘off first’ both received subgenual
ACC DBS could cast doubt on the findings in this part of the study.5. Disclosures
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